Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2018

View Archived Issues

First patient treated in phase I study of anti-CD47 monoclonal antibody SRF-231

Eli Lilly discovers novel PDE1 inhibitors

Novel serine protease HTRA1 inhibitors identified at Roche

Genentech and Roche present new HsNIK inhibitors

Technical University of Denmark presents ROS-activated methotrexate and aminopterin prodrugs

GlaxoSmithKline divulges novel bromodomain and extra-terminal protein inhibitors

DHX34 expression predicts poor survival in melanoma patients

SAR-191801, an orally active inhibitor of H-PGDS for asthma and COPD

Cosmo Pharmaceuticals submits NDA to the FDA or rifamycin SV MMX

First patient dosed in phase II psoriasis trial of ABY-035

Eiger BioPharmaceuticals receives FDA guidance for lornafarnib HDV development

Biodesix to collaborate with Checkmate Pharmaceuticals on treatment biomarkers

Researchers discover novel phyllanthusmin analog PHY-34

FDA grants fast track designation to Pedmark

Inhaled JAK1 inhibitors synthesized for treating asthma

Helix BioPharma and ProMab Biotechnologies to collaborate on CAR-T therapy

Swedish Orphan Biovitrum launches Ravicti in Europe

Boston Scientific to acquire NxThera

AOBiome Therapeutics' ammonia oxidizing bacteria product well tolerated in phase I study

New gene fusions detected in pleomorphic adenoma

Merus and Vall d'Hebron Institute of Oncology expand collaboration

Deinove enters option and license agreement for Redx's anti-infective program

Innate Biologics to develop recombinant protein platform with the Wistar Institute

Novartis signs licensing agreement for Harvard's biomaterial-based cancer immunotherapies

LSZ-102, a potent SERD showing good oral bioavailability and clinical safety

Bayer's acquisition of Monsanto gets conditional approval in Europe

Allysta initiates phase I/II study of H-1337 for elevated intraocular pressure

Bristol-Myers Squibb studies BMS-986258 alone and with nivolumab in advanced solid tumors

GlaxoSmithKline initiates first-in-human study of GSK-3358699

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...